Recently, Dario Amodei, CEO of leading AI company Anthropic, stated publicly in his company's IPO roadshow video that cancer, Alzheimer's disease, heart disease, and various severe mental illnesses, which have long plagued humanity, could potentially become history in less than 10 years.
During the roadshow, he mentioned that with proper regulatory guidance and practical application of AI technology, humanity could usher in a new era of miracles, solving stubborn diseases that have plagued civilization for millennia. Many conditions previously deemed incurable could find corresponding cures in a short period.
Earlier, in interviews with the media, Amodei had publicly stated that AI would fully have the capability to help humanity find cures for most cancers, intervene early in the progression of Alzheimer's disease, and even ultimately double the average human life expectancy.
He also introduced the novel concept of a "compressed 21st century," arguing that if AI can collaborate deeply with the world's top medical and biological scientists, the pace of medical research could accelerate to ten times its current rate. Medical exploration processes that might otherwise take the entire 21st century could potentially be completed in just 5 to 10 years.
As recently as this September, Amodei reiterated his judgment in a publicly published article, firmly believing that AI could conquer most major diseases plaguing humanity within the next 5 to 10 years, bringing revolutionary upgrades to global public healthcare systems.
In response to this highly impactful optimistic assessment, Dave Ricks, Chairman and CEO of Eli Lilly, one of the world's leading pharmaceutical companies, offered a rather pragmatic reply. He stated that while the vision is appealing, its actual realization is unlikely.
Dave Ricks explained that there are still vast unexplored gaps in human understanding of our own biological mechanisms. Obtaining sufficiently reliable clinical evidence through rigorous randomized human trials remains a key bottleneck that cannot be bypassed in determining the progress of drug and therapy development.
Ricks also admitted that he is equally excited about the prospects of AI applications in the pharmaceutical industry, but he predicts that future progress will likely be steady and gradual, rather than involving sudden, dramatic breakthroughs.
In other words, leveraging AI's superior computing power to faster screen suitable candidate drugs does not mean one can equally quickly prove their safety and efficacy for patients. Preliminary findings from the laboratory are still a long way from clinical application, requiring a full set of stringent validation processes to be completed.
The stark contrast between the optimistic expectations of AI industry practitioners and the cautious judgments of traditional pharmaceutical giants essentially reflects the fundamentally different industry logics of the two fields. While AI computing power can iterate at an exponential pace, clinical validation in life sciences allows for no shortcuts. No matter how cutting-edge the technology, it must ultimately safeguard patient safety.